Sign up to access all valuation multiples
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
2014
96
Last FY Revenue n/a
Last FY EBITDA -$20.1M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Guangzhou Innogen Pharma achieved revenue of n/a and an EBITDA of -$20.1M.
Guangzhou Innogen Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Guangzhou Innogen Pharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$20.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$24.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | -$22.4M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 5, 2025, Guangzhou Innogen Pharma's stock price is HKD 41 (or $5).
Guangzhou Innogen Pharma has current market cap of HKD 18.6B (or $2.4B), and EV of HKD 17.9B (or $2.3B).
See Guangzhou Innogen Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.4B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 5, 2025, Guangzhou Innogen Pharma has market cap of $2.4B and EV of $2.3B.
Guangzhou Innogen Pharma's trades at n/a EV/Revenue multiple, and -114.1x EV/EBITDA.
Equity research analysts estimate Guangzhou Innogen Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Guangzhou Innogen Pharma's P/E ratio is not available.
See valuation multiples for Guangzhou Innogen Pharma and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -114.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -94.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -106.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -107.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGuangzhou Innogen Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.3M for the same period.
Guangzhou Innogen Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Guangzhou Innogen Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Guangzhou Innogen Pharma and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guangzhou Innogen Pharma acquired XXX companies to date.
Last acquisition by Guangzhou Innogen Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Guangzhou Innogen Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Guangzhou Innogen Pharma founded? | Guangzhou Innogen Pharma was founded in 2014. |
| Where is Guangzhou Innogen Pharma headquartered? | Guangzhou Innogen Pharma is headquartered in Hong Kong. |
| How many employees does Guangzhou Innogen Pharma have? | As of today, Guangzhou Innogen Pharma has 96 employees. |
| Is Guangzhou Innogen Pharma publicy listed? | Yes, Guangzhou Innogen Pharma is a public company listed on HKG. |
| What is the stock symbol of Guangzhou Innogen Pharma? | Guangzhou Innogen Pharma trades under 02591 ticker. |
| When did Guangzhou Innogen Pharma go public? | Guangzhou Innogen Pharma went public in 2025. |
| Who are competitors of Guangzhou Innogen Pharma? | Similar companies to Guangzhou Innogen Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Guangzhou Innogen Pharma? | Guangzhou Innogen Pharma's current market cap is $2.4B |
| Is Guangzhou Innogen Pharma profitable? | Yes, Guangzhou Innogen Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
